Form 4: LifeMD CFO Atul Kavthekar Receives Equity Grant

LifeMD CFO Atul Kavthekar was granted 337,500 restricted stock units as part of an equity compensation package.

Summary

• Atul Kavthekar, Chief Financial Officer of LifeMD, Inc., received a grant of 337,500 restricted stock units (RSUs).
• The transaction occurred on May 11, 2026.
• The RSUs are subject to a multi-year vesting schedule.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation with no immediate impact on company operations.

Positives

• Equity grants align the interests of the CFO with long-term shareholder value creation.

Negatives

• The grant results in potential future dilution for existing shareholders.

Risks

• Vesting conditions are subject to the continued employment of the executive.

Future Outlook

The RSUs vest in three equal annual installments starting March 16, 2027, through March 16, 2029.

Industry Context

StockSavvy.ai notes that equity-based compensation for C-suite executives is a standard practice in the telehealth and digital health sectors to ensure retention and performance alignment.

Comparison to Industry Standards

• The use of multi-year vesting schedules for executive equity is consistent with standard corporate governance practices for publicly traded companies.

Stakeholder Impact

• Shareholders may experience minor dilution upon the vesting and issuance of the underlying common stock.

Next Steps

• Vesting of 112,500 shares on March 16, 2027.
• Vesting of 112,500 shares on March 16, 2028.
• Vesting of remaining shares on March 16, 2029.

Key Dates

Keywords

LifeMD, LFMD, Form 4, Insider Trading, Equity Compensation, CFO